12 terminated. 12 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Terminated 12 |
Follow Thromboembolism: new trials by email Literature Review of Thromboembolism trials Research Report on Thromboembolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test. Standard Enoxaparin 40 mg once-daily before randomization, Standard Enoxaparin 40 mg once-daily after randomization, Escalated Enoxaparin 30 mg twice-daily after randomization - Venous Thromboembolism | Phase 4 | Terminated | Pirogov Russian National Research Medical University | 9 | 2021-03-01 | 2025-01-07 |
| Apixaban for Extended Anticoagulation (APIDULCIS) Apixaban - Venous Thromboembolism, Anticoagulants | Phase 4 | Terminated | Arianna Anticoagulazione Foundation | 800 | 2018-08-16 | 2023-02-24 |
| Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism Warfarin, Apixaban 2.5 MG, Rivaroxaban 10 MG - Venous Thromboembolism | Phase 4 | Terminated | Duke University | 44 | 2018-08-01 | 2019-12-13 |
| Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin Enoxaparin - Anticoagulants and Bleeding Disorders, Surgery | Phase 4 | Terminated | Wake Forest University Health Sciences | 122 | 2017-10-24 | 2023-10-05 |
| PREvention of VENous ThromboEmbolism Following Radical Prostatectomy Subcutaneous Heparin - Prostate Cancer, Venous Thromboembolism | Phase 4 | Terminated | Johns Hopkins University | 501 | 2017-07-01 | 2020-08-05 |
| Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis apixaban - Deep Venous Thrombosis, Upper Extremity Deep Venous Thrombosis | Phase 4 | Terminated | Intermountain Health Care, Inc. | 52 | 2017-02-22 | 2023-09-28 |
| Aspirin and Enoxaparin for VTE in Trauma Aspirin, Enoxaparin - Venous Thromboembolism, Thromboprophylaxis | Phase 4 | Terminated | University of Miami | 31 | 2016-02-01 | 2019-11-19 |
| Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency fondaparinux - Medical Patients, Renal Insufficiency | Phase 4 | Terminated | Università degli Studi dell'Insubria | 206 | 2009-04-01 | 2012-04-24 |
| Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients Dalteparin (Fragmin), Unfractionated heparin - Venous Thromboembolism | Phase 4 | Terminated | Pfizer | 84 | 2007-06-01 | 2009-10-15 |
| Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications phenprocoumon - Mechanical Heart Valve Recipients | Phase 4 | Terminated | Heart and Diabetes Center North-Rhine Westfalia | 1571 | 2006-01-01 | 2013-12-11 |
| Thromboprophylaxis in Critically Ill Patients dalteparin - Venous Thromboembolism | Phase 4 | Terminated | Medical University of Vienna | 90 | 2003-04-01 | 2007-02-21 |
| Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study Dalteparin sodium, Placebo - Thromboembolism, Deep Vein Thrombosis | Phase 4 | Terminated | Pfizer | 8 | 2003-04-01 | 2008-09-29 |
Venous Thromboembolism (9) · Venous Thrombosis (4) · Pulmonary Embolism (2) · Thrombosis (2) · Critical Illness (1) · Heart Failure (1) · Hemorrhage (1) · Hemostatic Disorders (1) · Infections (1) · Inflammatory Bowel Diseases (1) · Prostatic Neoplasms (1) · Renal Insufficiency (1) · Sciatica (1) · Wounds and Injuries (1)
Cardiovascular Diseases (12) · Embolism and Thrombosis (12) · Vascular Diseases (12) · Pathological Conditions, Signs and Symptoms (3) · Thrombosis (3) · Embolism (2) · Lung Diseases (2) · Male Urogenital Diseases (2) · Pathologic Processes (2) · Respiratory Tract Diseases (2) · Urogenital Diseases (2) · Digestive System Diseases (1) · Disease Attributes (1) · Female Urogenital Diseases (1)
Dalteparin (3) · apixaban (3) · Enoxaparin (2) · Aspirin (1) · Fondaparinux (1) · Heparin (1) · Phenprocoumon (1) · Rivaroxaban (1) · Warfarin (1)
Pfizer (2) · Arianna Anticoagulazione Foundation (1) · Duke University (1) · Heart and Diabetes Center North-Rhine Westfalia (1) · Intermountain Health Care, Inc. (1) · Johns Hopkins University (1) · Medical University of Vienna (1) · Pirogov Russian National Research Medical University (1) · University of Miami (1) · Università degli Studi dell'Insubria (1) · Wake Forest University Health Sciences (1)
United States (5) · Italy (2) · Austria (1) · Germany (1) · India (1) · Russia (1) · Spain (1)
Alessandro Squizzato, MD (1) · Daniela Poli, MD (1) · Daryl S Henshaw, MD (1) · Francesco Dentali, MD (1) · Heinrich Koertke, MD (1) · Kenneth Proctor, PhD (1) · Kirill Lobastov, PhD (1) · Mohamad E Allaf, MD (1) · Scott Woller, MD (1) · Thomas Ortel, MD (1) · Ute Priglinger, MD (1) · Walter Ageno, MD (1)
PMID 22925036, PMID 28492441, PMID 30352714, PMID 31643128, PMID 32444264, PMID 35914222, PMID 37280083
2008 (1), 2017 (1)